The Journal of Pediatrics
Volume 151, Issue 3 , Pages 260-265.e1 , September 2007

Clinical Trial of Safety and Efficacy of IHN-A21 for the Prevention of Nosocomial Staphylococcal Bloodstream Infection in Premature Infants

  • Mitchell DeJonge, MD

      Affiliations

    • DeVos Children’s Hospital, Grand Rapids, Michigan
    • ,
  • David Burchfield, MD

      Affiliations

    • Shand’s Children’s Hospital, University of Florida, Gainesville, Florida
    • ,
  • Barry Bloom, MD

      Affiliations

    • Wesley Medical Center, Wichita, Kansas
    • ,
  • Maria Duenas, MD

      Affiliations

    • St. John Hospital and Medical Center, Detroit, Michigan
    • ,
  • Whit Walker, MD

      Affiliations

    • Greenville Memorial Hospital, Greenville, South Carolina
    • ,
  • Mark Polak, MD

      Affiliations

    • West Virginia University Hospital, Morgantown, West Virginia
    • ,
  • Elizabeth Jung, MD

      Affiliations

    • St. John’s Mercy Medical Center, St. Louis, Missouri
    • ,
  • Dietra Millard, MD

      Affiliations

    • Evanston Hospital, Evanston, Illinois
    • ,
  • Robert Schelonka, MD

      Affiliations

    • University of Alabama at Birmingham Hospital, Birmingham, Alabama
    • ,
  • Fabien Eyal, MD

      Affiliations

    • University of South Alabama Children’s & Women’s Hospital, Mobile, Alabama
    • ,
  • Amy Morris, MBA

      Affiliations

    • Inhibitex, Inc., Alpharetta, Georgia
    • ,
  • Barry Kapik, MS

      Affiliations

    • Inhibitex, Inc., Alpharetta, Georgia
    • ,
  • Destrey Roberson, RN

      Affiliations

    • Inhibitex, Inc., Alpharetta, Georgia
    • ,
  • Karen Kesler, PhD

      Affiliations

    • Rho, Inc., Chapel Hill, North Carolina.
    • ,
  • Joe Patti, PhD

      Affiliations

    • Inhibitex, Inc., Alpharetta, Georgia
    • ,
  • Seth Hetherington, MD

      Affiliations

    • Inhibitex, Inc., Alpharetta, Georgia
    • Corresponding Author InformationReprint requests: Seth Hetherington, MD, 4222 Emperor Blvd., Suite 335, Durham, NC 27703.

Received 20 November 2006 ,Revised 30 March 2007 ,Accepted 25 April 2007.

References 

  1. Martin JA, Hamilton BE, Ventura SJ, Menacker F, Park MM. Births: final data for 2000. Natl Vital Stat Rep. 2002;50:1–101
  2. Fanaroff AA, Hack M, Walsh MC. The NICHD neonatal research network: changes in practice and outcomes during the first 15 years. Semin Perinatol. 2003;27:281–287
  3. Fanaroff AA, Korones SB, Wright LL, Verter J, Poland RL, Bauer CR, et al. Incidence, presenting features, risk factors and significance of late onset septicemia in very low birth weight infants (The National Institute of Child Health and Human Development Neonatal Research Network). Pediatr Infect Dis J. 1998;17:593–598
  4. Stoll BJ, Gordon T, Korones SB, Shankaran S, Tyson JE, Bauer CR, et al. Late-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr. 1996;129:63–71
  5. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics. 2002;110:285–291
  6. Stoll BJ, Hansen NI, Adams-Chapman I, Fanaroff AA, Hintz SR, Vohr B, et al. Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. JAMA. 2004;292:2357–2365
  7. Fanaroff AA, Korones SB, Wright LL, Wright EC, Poland RL, Bauer CB, et al. A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants (National Institute of Child Health and Human Development Neonatal Research Network). N Engl J Med. 1994;330:1107–1113
  8. Hill HR. Additional confirmation of the lack of effect of intravenous immunoglobulin in the prevention of neonatal infection. J Pediatr. 2000;137:595–597
  9. Ohlsson A, Lacy JB. Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants. Cochrane Database Syst Rev. 2004;CD000361
  10. Baker CJ, Melish ME, Hall RT, Casto DT, Vasan U, Givner LB. Intravenous immune globulin for the prevention of nosocomial infection in low-birth-weight neonates (The Multicenter Group for the Study of Immune Globulin in Neonates). N Engl J Med. 1992;327:213–219
  11. Healy CM, Palazzi DL, Edwards MS, Campbell JR, Baker CJ. Features of invasive staphylococcal disease in neonates. Pediatrics. 2004;114:953–961
  12. Bloom B, Schelonka R, Kueser T, Walker W, Jung E, Kaufman D, et al. Multicenter study to assess safety and efficacy of INH-A21, a donor-selected human staphylococcal immunoglobulin, for prevention of nosocomial infections in very low birth weight infants. Pediatr Infect Dis J. 2005;24:858–866
  13. Vernachio J, Bayer AS, Le T, Chai YL, Prater B, Schneider A, et al. Anti-clumping factor A immunoglobulin reduces the duration of methicillin-resistant Staphylococcus aureus bacteremia in an experimental model of infective endocarditis. Antimicrob Agents Chemother. 2003;47:3400–3406
  14. Patti JM, Allen BL, McGavin MJ, Hook M. MSCRAMM-mediated adherence of microorganisms to host tissues. Annu Rev Microbiol. 1994;48:585–617
  15. Höök M, Patti JM, McGavin M, Gurusiddappa S, Lindgren PE, Jönsson K, et al. MSCRAMMs-microbial recognition systems for extracellular matrix molecules. In: Wadström T, Holder, I, and Kronvall, G, eds Molecular Pathogenesis of Surgical Infections. Stuttgart: Gustav Fischer Verlag; 1994137-44.
  16. Capparelli EV, Bloom BT, Kueser TJ, Oelberg DG, Bifano EM, White RD, et al. Multicenter study to determine antibody concentrations and assess the safety of administration of INH-A21, a donor-selected human staphylococcal immune globulin, in low-birth-weight infants. Antimicrob Agents Chemother. 2005;49:4121–4127
  17. Krediet TG, Beurskens FJ, van Dijk H, Gerards LJ, Fleer A. Antibody responses and opsonic activity in sera of preterm neonates with coagulase-negative staphylococcal septicemia and the effect of the administration of fresh frozen plasma. Pediatr Res. 1998;43:645–651
  18. Fischer GW, Cieslak TJ, Wilson SR, Weisman LE, Hemming VG. Opsonic antibodies to Staphylococcus epidermidis: in vitro and in vivo studies using human intravenous immune globulin. J Infect Dis. 1994;169:324–329
  19. Etzioni A, Obedeanu N, Blazer S, Benderly A, Merzbach D. Effect of an intravenous gammaglobulin preparation on the opsonophagocytic activity of preterm serum against coagulase-negative staphylococci. Acta Paediatr Scand. 1990;79:156–161
  20. Clark LA, Easmon CS. Opsonic requirements of Staphylococcus epidermidis. J Med Microbiol. 1986;22:1–7
  21. Christensen RD, Hardman T, Thornton J, Hill HR. A randomized, double-blind, placebo-controlled investigation of the safety of intravenous immune globulin administration to preterm neonates. J Perinatol. 1989;9:126–130
  22. Fischer GW. Use of intravenous immune globulin in newborn infants. Clin Exp Immunol. 1994;97(suppl 1):73–77
  23. Jenson HB, Pollock BH. Meta-analyses of the effectiveness of intravenous immune globulin for prevention and treatment of neonatal sepsis. Pediatrics. 1997;99:E2;http://www.pediatrics.org/cgi/content/full/99/z/e2.
  24. Vernachio JH, Bayer AS, Ames B, Bryant D, Prater BD, Syribeys PJ, et al. Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo. Antimicrob Agents Chemother. 2006;50:511–518
  25. Lin FY, Weisman LE, Azimi PH, Philips JB, Clark P, Regan J, et al. Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen. J Infect Dis. 2004;190:928–934
  26. Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med. 2002;346:491–496
  27. Ahsan N, Wiegand LA, Abendroth CS, Manning EC. Acute renal failure following immunoglobulin therapy. Am J Nephrol. 1996;16:532–536
  28. Brannagan TH, Nagle KJ, Lange DJ, Rowland LP. Complications of intravenous immune globulin treatment in neurologic disease. Neurology. 1996;47:674–677
  29. Cantu TG, Hoehn-Saric EW, Burgess KM, Racusen L, Scheel PJ. Acute renal failure associated with immunoglobulin therapy. Am J Kidney Dis. 1995;25:228–234
  30. Michail S, Nakopoulou L, Stavrianopoulos I, Stamatiadis D, Avdikou K, Vaiopoulos G, et al. Acute renal failure associated with immunoglobulin administration. Nephrol Dial Transplant. 1997;12:1497–1499
  31. Sati HI, Ahya R, Watson HG. Incidence and associations of acute renal failure complicating high-dose intravenous immunoglobulin therapy. Br J Haematol. 2001;113:556–557
  32. Cayco AV, Perazella MA, Hayslett JP. Renal insufficiency after intravenous immune globulin therapy: a report of two cases and an analysis of the literature. J Am Soc Nephrol. 1997;8:1788–1794
  33. Hansen-Schmidt S, Silomon J, Keller F. Osmotic nephrosis due to high-dose immunoglobulin therapy containing sucrose (but not with glycine) in a patient with immunoglobulin A nephritis. Am J Kidney Dis. 1996;28:451–453
  34. Casteels-Van Daele M, Wijndaele L, Hanninck K, Gillis P. Intravenous immune globulin and acute aseptic meningitis. N Engl J Med. 1990;323:614–615
  35. Scribner CL, Kapit RM, Phillips ET, Rickles NM. Aseptic meningitis and intravenous immunoglobulin therapy. Ann Intern Med. 1994;121:305–306
  36. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med. 1994;121:259–262
  37. Lassiter HA, Bibb KW, Bertolone SJ, Patel CC, Stroncek DF. Neonatal immune neutropenia following the administration of intravenous immune globulin. Am J Pediatr Hematol Oncol. 1993;15:120–123
  38. Gladstone IM, Ehrenkranz RA, Edberg SC, Baltimore RS. A ten-year review of neonatal sepsis and comparison with the previous fifty-year experience. Pediatr Infect Dis J. 1990;9:819–825

 This study is registered at www.clinicaltrials.gov; registration number = NCT00113191.

 The study was funded in its entirety by Inhibitex, Inc. A. Morris, B. Kapik, D. Roberson, J. Patti, and S. Hetherington were all employees of Inhibitex during the course of the study.

PII: S0022-3476(07)00404-0

doi: 10.1016/j.jpeds.2007.04.060

The Journal of Pediatrics
Volume 151, Issue 3 , Pages 260-265.e1 , September 2007

Article Tools

* Image Usage & Resolution